After the success of CD19 CAR-T in B-cell non-Hodgkin lymphoma (B-NHL) in 2008 (21), in refractory chronic lymphocytic leukemia (CLL) in 2011 (22) and in refractory and relapsed ALL in 2013 (23), studies of CAR-based cell therapy entered the fast lane. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.